Traws Pharma, Inc. — Director's Dealing 2017

Apr 25, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2017-04-21

Reporting Person: TYNDALL CAPITAL PARTNERS L P (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-04-21	Common Stock	A	476190	$2.10	Acquired	997022	Indirect

Footnotes

F1: As of April 21, 2017, Tyndall Partners, L.P., a Delaware limited partnership ("Tyndall"), held 997,022 shares of common stock, par value $0.01 per share ("Shares"), and warrants to purchase up to 390,624 Shares. Tyndall Capital Partners, L.P. is the general partner of Tyndall Capital Partners L.P. ("Tyndall Capital"), and possesses the sole power to vote and the sole power to direct the disposition of all Shares and other securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any